Article in Journal of enzyme inhibition and medicinal chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
13 authors.
Anna StankiewiczDepartment of Medicinal Chemistry, Maj Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland.
Katarzyna KaczorowskaDepartment of Medicinal Chemistry, Maj Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland.ORCID 0000-0001-9221-947X
Ryszard BugnoDepartment of Medicinal Chemistry, Maj Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland.ORCID 0000-0003-3741-674X
Aneta KoziołDepartment of Medicinal Chemistry, Maj Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland.
Maria H PaluchowskaDepartment of Medicinal Chemistry, Maj Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland.ORCID 0000-0001-9843-2298
Grzegorz BurnatDepartment of Neurobiology, Maj Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland.ORCID 0000-0002-2300-0850
Barbara ChruścickaDepartment of Neurobiology, Maj Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland.ORCID 0000-0003-0189-3712
Paulina ChorobikDepartment of Neurobiology, Maj Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland.ORCID 0000-0002-3711-1594
Piotr BrańskiDepartment of Neurobiology, Maj Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland.ORCID 0000-0001-6126-0269
Joanna M WierońskaDepartment of Neurobiology, Maj Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland.
Beata DuszyńskaDepartment of Medicinal Chemistry, Maj Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland.ORCID 0000-0002-1487-3406
Andrzej PilcDepartment of Neurobiology, Maj Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland.ORCID 0000-0002-4045-0597
Andrzej J BojarskiDepartment of Medicinal Chemistry, Maj Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland.ORCID 0000-0003-1417-6333
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
Considering the allosteric regulation of mGlu receptors for potential therapeutic applications, we developed a group of 1,2,4-oxadiazole derivatives that displayed mGlu
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
New 1,2,4-oxadiazole derivatives with positive mGlu · full record | OpenQuestion